Published in Biol Psychiatry on September 01, 2005
Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry (2012) 1.83
Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). Neuropsychopharmacology (2010) 1.25
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
Increased extracellular concentrations of norepinephrine in cortex and hippocampus following vagus nerve stimulation in the rat. Brain Res (2006) 1.16
Vagal nerve stimulation rapidly activates brain-derived neurotrophic factor receptor TrkB in rat brain. PLoS One (2012) 1.03
Research advances in geriatric depression. World Psychiatry (2009) 1.03
Advances in the treatment of depression. NeuroRx (2006) 1.03
Heart rate variability in bipolar mania and schizophrenia. J Psychiatr Res (2009) 1.03
Chronic vagus nerve stimulation for treatment-resistant depression decreases resting ventromedial prefrontal glucose metabolism. Neuroimage (2008) 0.99
Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: a review. Brain Stimul (2010) 0.96
Chronic vagus nerve stimulation induces neuronal plasticity in the rat hippocampus. Int J Neuropsychopharmacol (2009) 0.96
Pretreatment cerebral metabolic activity correlates with antidepressant efficacy of vagus nerve stimulation in treatment-resistant major depression: a potential marker for response? J Affect Disord (2012) 0.93
Bilateral epidural prefrontal cortical stimulation for treatment-resistant depression. Biol Psychiatry (2010) 0.92
"Getting physical": the management of neuropsychiatric disorders using novel physical treatments. Neuropsychiatr Dis Treat (2006) 0.92
Deep brain stimulation for treatment-resistant depression. Am J Psychiatry (2010) 0.92
Vagus nerve stimulation for epilepsy and depression. Neurotherapeutics (2008) 0.92
Vagus Nerve Stimulation. Curr Behav Neurosci Rep (2014) 0.90
Guidelines for Reporting Articles on Psychiatry and Heart rate variability (GRAPH): recommendations to advance research communication. Transl Psychiatry (2016) 0.89
Comparative Study of Heart Rate Variability in Patients with Schizophrenia, Bipolar Disorder, Post-traumatic Stress Disorder, or Major Depressive Disorder. Clin Psychopharmacol Neurosci (2013) 0.86
A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. Med Devices (Auckl) (2013) 0.85
Vagus Nerve Stimulation (VNS) and Treatment of Depression: To the Brainstem and Beyond. Psychiatry (Edgmont) (2006) 0.84
Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine. Clin Psychopharmacol Neurosci (2014) 0.83
Nonpharmacological, somatic treatments of depression: electroconvulsive therapy and novel brain stimulation modalities. Dialogues Clin Neurosci (2006) 0.82
Somatic treatments for mood disorders. Neuropsychopharmacology (2011) 0.82
Emerging targets for antidepressant therapies. Curr Opin Chem Biol (2009) 0.82
Future prospects in depression research. Dialogues Clin Neurosci (2006) 0.81
Novel targets for antidepressant therapies. Curr Psychiatry Rep (2008) 0.80
Vagal Nerve Stimulation for Treatment-Resistant Depression. Neurotherapeutics (2017) 0.80
Vagal nerve stimulation reverses aberrant dopamine system function in the methylazoxymethanol acetate rodent model of schizophrenia. J Neurosci (2014) 0.79
Mortality and suicide risk in treatment-resistant depression: an observational study of the long-term impact of intervention. PLoS One (2012) 0.79
Evolving refractory major depressive disorder diagnostic and treatment paradigms: toward closed-loop therapeutics. Front Neuroeng (2010) 0.79
Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy. Front Psychiatry (2015) 0.77
Number of risk genotypes is a risk factor for major depressive disorder: a case control study. Behav Brain Funct (2006) 0.76
Neuromodulation for treatment-resistant depression. F1000 Med Rep (2012) 0.76
Responding to three articles regarding vagus nerve stimulation (VNS) for depression. Biol Psychiatry (2006) 0.76
Promising avenues of therapeutics for bipolar illness. Dialogues Clin Neurosci (2008) 0.76
Vagus nerve stimulation in psychiatry: a systematic review of the available evidence. J Neural Transm (Vienna) (2016) 0.76
Vagus nerve stimulation for treatment-resistant mood disorders: a long-term naturalistic study. BMC Psychiatry (2015) 0.75
Vagus Nerve Stimulation Alters Phase Synchrony of the Anterior Cingulate Cortex and Facilitates Decision Making in Rats. Sci Rep (2016) 0.75
Impaired heart rate variability in cervical dystonia is associated to depression. J Neural Transm (Vienna) (2016) 0.75
[Brain stimulation methods for resistance to therapy]. Nervenarzt (2007) 0.75
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 34.83
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials (2004) 6.64
Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA (2006) 6.26
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry (2007) 5.59
Medication augmentation after the failure of SSRIs for depression. N Engl J Med (2006) 5.16
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am (2003) 5.05
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry (2008) 4.98
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry (2006) 3.90
Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry (2004) 3.84
Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology (2006) 3.80
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry (2006) 3.72
Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2006) 3.66
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2004) 3.43
Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry (2008) 3.40
Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry (2007) 3.38
Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry (2010) 3.14
Estimating Individualized Treatment Rules Using Outcome Weighted Learning. J Am Stat Assoc (2012) 3.13
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry (2006) 3.01
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry (2006) 2.90
Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry (2007) 2.87
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry (2007) 2.84
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Parietal cortex and representation of the mental Self. Proc Natl Acad Sci U S A (2004) 2.73
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
Prefrontal and striatal dopaminergic genes predict individual differences in exploration and exploitation. Nat Neurosci (2009) 2.64
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry (2011) 2.58
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A (2003) 2.56
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet (2006) 2.55
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry (2005) 2.50
STAR*D: what have we learned? Am J Psychiatry (2007) 2.47
Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry (2007) 2.43
Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. Am J Psychiatry (2008) 2.42
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology (2008) 2.31
Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry (2005) 2.24
VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology (2006) 2.24
Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry (2004) 2.24
A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry (2006) 2.21
Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology (2005) 2.21
Response inhibition predicts poor antidepressant treatment response in very old depressed patients. Am J Geriatr Psychiatry (2007) 2.18
Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. JAMA (2010) 2.16
Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci (2007) 2.12
Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry (2004) 2.11
The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep (2007) 2.08
Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis. Arch Neurol (2003) 2.08
Measurement of IgE to pollen allergen components is helpful in selecting patients for immunotherapy. Ann Allergy Asthma Immunol (2013) 2.06
Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS (2004) 2.00
Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. J Psychiatr Res (2013) 1.99
Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry (2005) 1.99
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Treatment outcomes in depression: comparison of remote treatment through telepsychiatry to in-person treatment. Am J Psychiatry (2004) 1.96
Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry (2009) 1.96
Adequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: a prospective study. Am J Psychiatry (2002) 1.95
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
Early physical and sexual abuse associated with an adverse course of bipolar illness. Biol Psychiatry (2002) 1.93
Methodological challenges in constructing effective treatment sequences for chronic psychiatric disorders. Neuropsychopharmacology (2006) 1.93
Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry (2005) 1.90
Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry (2006) 1.90
Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia. Bipolar Disord (2009) 1.90
Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract (2006) 1.89
Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry (2007) 1.88
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry (2008) 1.86
Genome-wide association study of suicide attempts in mood disorder patients. Am J Psychiatry (2010) 1.85
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry (2010) 1.82
Gender differences in depression: findings from the STAR*D study. J Affect Disord (2005) 1.80
Prevalence of major depressive episode in CKD. Am J Kidney Dis (2009) 1.79
Effect of age at onset on the course of major depressive disorder. Am J Psychiatry (2007) 1.78
A new approach to spatial covariance modeling of functional brain imaging data: ordinal trend analysis. Neural Comput (2005) 1.78